Abstract:
Compounds of the formula (I) or (II) wherein R1 is C1-C10haloalkylsulfonyl, halobenzenesulfonyl, C2-C10haloalkanoyl, halobenzoyl; R2 is halogen or C1-C10haloalkyl; Arl is phenyl, biphenylyl, fluorenyl, naphthyl, anthracyl, phenanthryl, or heteroaryl, all of which are optionally substituted; Ar'1 is for example phenylene, naphthylene, diphonylene, heteroarylene, oxydiphenylene, phenyleneD-D1-D-phenylene or -A r'1-A1-Y1-A1-A r'1-; wherein these radicals optionally are substituted; Ae', is phenylene, naphthylene, anthracylene, phenanthrylene, or heteroarylene, all optionally substituted; A, is for exampfe a direct bond, -0-, -S-, or -NR6-; Y, inter alia is C1-C18alkylene; X is halogen; D is for example -0-, -S- or -NR6-; D, inter alia is C1-C18alkylene; are particularly suitable as photolatent acids in ArF resist technology.
Abstract:
New oxime derivatives of formula (I) or (II), wherein m is 0 or 1; R1 inter alia is phenyl, naphthyl, anthracyl, phenanthryl or a heteroaryl radical; R'1 is for example C2-C12alkylene, phenylene, naphthylene; R2 is CN; R3 is C2-C6haloalkanoyl, halobenzoyl, a phosphoryl or an organosilyl group; R4, R5, R10 and R11 inter alia are hydrogen, C1-C6alkyl, C1-C6alkoxy; R6 inter alia is hydrogen, phenyl, C1-C12alkyl; R7 and R8 inter alia are hydrogen, C1-C12alkyl; or R7 and R8, together with the nitrogen atom to which they are bonded, form a 5-, 6- or 7-membered ring; R9 is for example C1-C12alkyl; and A inter alia is S, O, NR7a; are useful as latent acids, especially in photoresist applications.
Abstract:
Disclosed are carbonates of general formula (I): A-O-CO-OR , in which A is a radical (Ia) R R C=N- or a radical (Ib), or the hydromidesters of the general formula (I) or the polymer derivates thereof are used with radicals having the meaning of R to R , especially alkyl and aryl with or without substituents, R /R representing inter alia hydrogen or, jointly, an alkyl group, while R /R represent inter alia jointly an alkyl group and R /R a carbocycle, as activators for anorganic per compounds.
Abstract translation:通式(I)的碳酸酯:AO-CO-OR <3>,在A(Ia)的一个残基R <1> [R <2>是C = N-或A为基团(Ib)中,或一般Hydroximidester 式(II),或者它们的聚合物,具有的含义R <1>至R除其他事项外<5>残余 烷基,芳基具有或不具有取代基,R <1> / R <2>等 也氢,或一起为亚烷基,R <4> / R <5>等 一起的亚烷基,R <6> / R <7>是一个碳环被用作活化剂为无机每。
Abstract:
본 발명은 신규한 옥심에스테르 유도체 화합물, 이를 포함하는 광중합 개시제 및 포토레지스트 조성물에 관한 것으로, 상세하게 본 발명에 따른 옥심에스테르 유도체 화합물은 감도, 내열성, 내광성, 내화학성 및 내현상성이 우수하여 소량의 사용으로도 TFT-LCD 제조 공정 중의 노광 및 포스트베이크 공정 등에 효과적인 광중합 개시제 및 포토레지스트 조성물을 제공할 수 있다.
Abstract:
The present invention relates to a dendritic photoactive compound that comprises oxime ester and a method for producing the same. Since the compound according to the present invention comprises two or more oxime ester groups and chromophores in one molecule at the same time, the solubility in respects to the organic solvent and the efficiency for producing a radical by absorbing ultraviolet rays are excellent. In addition, it can act as an effective initiator in respects to the photopolymerization of the unsaturated group, in particular, the acryl compound
Abstract:
Disclosed herein are embodiments of a bi-functionalized dicyclopentadiene monomer and polymer embodiments formed therefrom. The monomer embodiments exhibit tunability and can be used to form thermally stable homopolymers, copolymers, and/or crosslinked polymers.
Abstract:
The present invention relates to compounds having a 1,4-benzoquinone or 1,4- benzoquinone imine scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said 1,4- benzoquinone or 1,4-benzoquinone imine compounds can be used for prophylaxis and/or treatment of cancer and for prophylaxis and/or treatment of inflammatory diseases.
Abstract:
Inorganic per compounds may be activated with oxime carbonates of the formula (I), A-O-CO-OR3, a hydroximide ester of formula (II):or polymeric hydroximide esters.
Abstract:
An object of the present invention is to provide a novel ascochlorin derivative which activates adenosine monophosphate-activated protein kinase (AMPK), and is useful in the treatment or prevention of diseases or conditions that involve AMPK dysregulation. The present invention provides a compound presented by formula I, a pharmaceutically acceptable salt or a solvate thereof.